by open-label TAF through Year 8. Patients with hepatic decompensation, co-infection with HCV/HDV/HIV, or evidence of HCC were excluded. HCC was assessed at 6 monthly intervals by hepatic ultrasonography beginning after Week 96 and by local standards of care. The standardized incidence ratio (SIR) for HCC was calculated for observed cases relative to predicted cases using the REACH-B model.

Results 1632 patients were followed for up to 4 years; HCC was seen in 16 patients (0.98%; 7 TAF; 9 TDF); median time to onset was 568 days. At baseline HCC patients were older (median age 53 vs 40 y; p<0.001), had lower median HBV DNA (6.2 vs 7.3 log₁₀ IU/mL; p=0.041) and were more likely to have cirrhosis (FibroTest score 0.75; 31% vs 10%; p=0.004). For study patients, the overall SIR was significantly reduced with TAF or TDF treatment 0.45 (95% CI 0.278 -0.740) (table 1). HCC incidence was significantly reduced (SIR 0.42, 95% CI 0.23 to 0.75) in noncirrhotic patients (n=11 vs 26.5 predicted), but not for cirrhotic patients (n=5 vs 8.1 predicted). The SIR was significantly reduced in noncirrhotic patients receiving TAF (n=5), but not in those with TDF (n=6).

Conclusions In CHB patients treated with TAF or TDF for up to 4 years, HCC incidence was reduced, particularly in noncirrhotic patients. Additional follow up is needed to further characterize the impact of longer-term treatment on HCC risk reduction.

IDDF2020-ABS-0062 EXPLORATORY DATA ANALYSIS OF MIMIC-III DATABASE AND PREDICTING MORTALITY OF ACUTE HEPATIC FAILURE

Yi Yu*. Department of Critical Care Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, China

10.1136/gutjnl-2020-IDDF.145

Background Using MIMIC-III database to establish a machine learning method to predict the risk prediction model of mortality in patients with acute hepatic failure, assisting clinicians in clinical decision making.

Methods We collected the demographics, physiological and biochemical parameters of the patients 24 hours before admission, and the variability and dynamic characteristics contained in the target patient as explanatory variables. In-hospital mortality was used as an outcome variable. Excellent machine learning algorithms such as random forest, xgboost, etc. were used to establish classification models to predict the severity of the acute hepatic failure.

Results The proportion of diseases of different systems changing with age was obtained, and the characteristics of the disease spectrum in MIMIC-III database were explored and interpreted. In 1,037 patients with acute hepatic failure, the optimal AUC of prediction models established using random forest and xgboost machine learning algorithms reached 0.88 [0.86, 0.90], which outperformed traditional SOFA and SAPS

Conclusions The performance of the model is better than the traditional clinically used scores. It can help clinicians to identify patients' risk of deterioration and death early. Clinical decision-making provides supports and can be used as a reference for developing next-generation disease severity scores. The application of analytics based on big data in the medical field provides us with more reliable technical means for understanding the development process, early diagnosis, and clinical decision support.


IDDF2020-ABS-0063


UNRESECTABLE HEPATOCELLULAR CARCINOMA: TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION COMBINED WITH MICROWAVE ABLATION VERSUS COMBINED WITH CRYOABLATION

Jialiang Wei*, Jiaping Li, Wenzhe Fan. Department of Interventional Oncology, the First Affiliated Hospital, Sun Yat-sen University, China

10.1136/gutjnl-2020-IDDF.146

Background Transcatheter arterial chemoembolization (TACE) combined with ablation has been widely used for treating unresectable hepatocellular carcinoma (HCC). However, the technique with which TACE should be combined for it to be more effective remains unknown. To evaluate the efficacy and





Abstract IDDF2020-ABS-0063 Figure 1 Kaplan-Meier curves of OS

A76 Gut 2020;69(Suppl 2):A1-A95